Source: Ituran Location and Control Ltd. 6/12/2025
turan Location and Control Ltd. (NASDAQ: ITRN), a
global leader in vehicle telematics, through its Brazilian subsidiary,
and BMW Motorrad Brasil, a leader in premium motorcycle sales in Brazil,
have launched a strategic partnership to offer telematics services to
BMW's customers, offering rider safety, security, and connectivity. The
initiative introduces a new experience for BMW Motorrad customers in Brazil, powered by Ituran's advanced technology.
Ituran & BMW Motorrad in Brazil: Security & Connectivity
with Your Motorcycle, Make Life a Ride. With Ituran, you get security
and technology
The partnership offers BMW Motorrad riders a unique
experience that combines advanced safety and connectivity features. The
service offers security technology for the customer and their
motorcycle, using state-of-the-art telematics and access to the Ituran
app, with real-time location tracking, virtual geofencing, route
history, risk zone heat maps, maintenance alerts, digital service
integration, and vehicle recovery services.
"We are always looking to deliver the best experience
to our BMW Motorrad customers. This new partnership with Ituran enables
us to jointly develop a fully comprehensive offering that goes beyond
traditional tracking, providing new forms of connectivity with the
motorcycle, to receive updates from BMW Motorrad and its dealers, and
enjoy an integrated digital experience," said Matheus Pereira, CEO of BMW Motorrad in Brazil.
"For new motorcycles, BMW Motorrad customers will have 24 months of
free access to the Ituran service. For other BMW Motorrad customers, we
offer special conditions so they can enjoy the same experience," added
Pereira.
"We are proud to collaborate with BMW Motorrad, a
global leader in motorcycle technology and quality. For us, it is a
strategic partnership in a highly relevant segment that significantly
expands our total addressable market, with the addition of this large
base of motorcycle customers," said Eyal Sheratzky, CEO of Ituran.
"This initiative further strengthens Ituran Brasil's innovation
leadership in a country that is a strong contributor to our global
growth."
About BMW Group
With its four brands BMW,
MINI, Rolls-Royce, and BMW Motorrad, BMW Group is the world's leading
premium manufacturer of automobiles and motorcycles and also provides
premium financial services. BMW Group's production network comprises
more than 30 production sites worldwide; the company has a global sales
network in more than 140 countries.
In 2024, BMW Group sold more than 2.45 million passenger vehicles and more than 210,000 motorcycles worldwide. As of December 31, 2024, BMW Group had a workforce of 159,104 employees.
BMW
Group's economic success has always been based on long-term thinking
and responsible action. Sustainability is a key element of BMW Group's
corporate strategy and encompasses all products, from the supply chain
and production to the usage phase.
About Ituran
Ituran
is a leader in the mobility technology field, providing value-added
location-based services, including a full suite of services for the
connected-car. Ituran offers Stolen Vehicle Recovery, fleet management
as well as mobile asset location, management & control services for
vehicles, cargo and personal security for the retail, insurance industry
and car manufacturers. Ituran is the largest OEM telematics provider in
Latin America. Its products and applications are used by customers in over 20 countries. Ituran is also the founder of the Tel-Aviv based DRIVE startup incubator to promote the development of smart mobility technology.
Ituran's
subscriber base has been growing significantly since the Company's
inception to over 2.5 million subscribers using its location-based
services with a market leading position in Israel and Latin America. Established in 1995, Ituran has approximately 2,800 employees worldwide, with offices in Israel, Brazil, Argentina, Mexico, Ecuador, Columbia, India, Canada and the United States.
Source: Ituran Location and Control Ltd. 5/28/2025
Ituran Location and Control Ltd. (NASDAQ: ITRN) announced that the Board of Directors approved the distribution of a cash dividend in the amount of $0.50 per share, totaling approximately US$ 10 million. The dividend will be paid to shareholders of record as of June 18, 2025. The Company will pay the dividend out on July 2, 2025, net of taxes at the rate of 25%.
In its decision to approve the distribution of the
cash dividend, the Board of Directors examined whether the Company meets
the distribution criteria according to Israeli law. The Board of
Directors concluded that the above-mentioned distribution will not
undermine the Company's ability to keep performing in its current course
of business or future plans, and is able to meet its undertakings when
due.
Retained earnings as of March 31, 2025, prior to the distribution was US$ 230.7 million and retained earnings will reach US$ 220.7 million after the distribution. The Board of Directors emphasized that as of March 31, 2025, the Company had a cash balance in hand of US$ 75.7 million (this amount is prior to the payment of a dividend of approximately US$ 10 million which was issued for the fourth quarter 2024 and was paid out in April 2025). The Company had no credit from banking institutions. As of March 31, 2025, the Company's current assets (excluding cash and cash equivalents) were in the sum of US$ 125.7 million and current liabilities were in the sum of US$ 93.3 million.
About Ituran Ituran is a leader
in the emerging mobility technology field, providing value-added
location-based services, including a full suite of services for the
connected-car. Ituran offers Stolen Vehicle Recovery, fleet management
as well as mobile asset location, management & control services for
vehicles, cargo and personal security for the retail, insurance industry
and car manufacturers. Ituran is the largest OEM telematics provider in
Latin America. Its products and applications are used by customers in over 20 countries. Ituran is also the founder of the Tel-Aviv based DRIVE startup incubator to promote the development of smart mobility technology.
Ituran's subscriber base has been growing
significantly since the Company's inception to over 2.5 million
subscribers using its location-based services with a market leading
position in Israel and Latin America. Established in 1995, Ituran has approximately 2,800 employees worldwide, with offices in Israel, Brazil, Argentina, Mexico, Ecuador, Columbia, India, Canada and the United States.
Source: Ituran Location and Control Ltd. 5/28/2025
Surpasses 2.5 million subscriber milestone with 99,000 net adds in
the quarter; raises 2025 net subscriber-add forecast to
220,000–240,000;
Ituran Location and Control Ltd. (NASDAQ: ITRN) today announced its consolidated financial results for the first quarter 2025.
Highlights of the First Quarter of 2025
Added a record 99,000 net subscribers in the quarter.
Revenue of $86.5 million, a 2% increase year-over-year.
Operating income of $18.7 million, a 10% increase year-over-year.
Net income increased to $14.6 million, a 12% increase year-over-year.
EBITDA grew to $23.3 million, a 4% increase year-over-year.
The Board declared a quarterly dividend of $10 million, or $0.50 per share.
Management Comment
Eyal Sheratzky, Co-CEO of Ituran said, "We are very pleased
with our strong start to 2025, marked by continued revenue and profit
growth. Significantly, Ituran reached a major milestone in the quarter,
crossing 2.5 million subscribers, ahead of plan. During the quarter, the
higher than typical subscriber growth was due to an additional
contribution from a new telematics service agreement signed with
Stellantis. Stellantis is the largest car manufacturer in Latin America,
which includes car brands Fiat, Jeep, Peugeot and many others. As an
initial part of our agreement, in March, Stellantis switched its SVR
subscriber base to Ituran and Ituran began providing services to their
subscribers. As such, we increase our expectations for 2025 subscriber
growth to between 220,000 and 240,000 net new subscribers."
Mr. Sheratzky continued, "We continue to work on developing
attractive new and advanced telematics products and services adding
value to our large and growing customer base through cutting-edge
technologies. We see good performance from our stolen vehicle recovery
business as well as solid traction for our new products – especially
telematic services for motorcycle and financing products in Latin America.
All this has been contributing to our accelerating subscriber growth.
Overall, 2025 is shaping up to be another year of solid growth and
profitability for Ituran."
First Quarter 2025 Results
Revenues for the quarter were $86.5 million, a 2% increase compared with $85.0 million in the first quarter of 2024.
72% of revenues were from location-based service subscription fees, and 28% were from product revenues.
It is noted that the first quarter strength of the US dollar versus
the various local currencies in which the Company operates compared to
the year-ago US dollar level, impacted the revenue growth when
translated into US dollars. In local currencies, revenues grew by 7%
year-over-year.
Revenues from subscription fees for the quarter were $62.2 million, an increase of 2% over the first quarter of 2024. In local currencies, subscription revenue grew by 9% year-over-year.
The subscriber base surpassed Ituran's 2.5 million milestone during the quarter, and expanded to 2,508,000 by the end of March 2025, marking a quarterly increase of 99,000.
The significant growth in the subscriber base during the quarter was
partially due to the contribution from a new telematics service
agreement signed with Stellantis. As an initial part of this agreement,
in March, Stellantis switched their SVR subscriber base to Ituran and
Ituran began providing services to these subscribers.
Product revenues for the quarter were $24.3 million, an increase of 1% year-over-year. In local currencies, product revenue grew by 3% year-over-year.
Gross profit for the quarter was $42.0 million (48.6% of revenues), a 6% increase compared with $39.5 million (46.5% of revenues) in the first quarter of 2024. In local currencies, gross profit grew by 10% year-over-year.
Gross margin on subscription revenues improved to 58.3%,
compared to 58.1% in Q1 2024. The gross margin on product revenues
improved to 23.6%, compared to 17.1% last year. The variance in the
product gross margin between quarters was due to the change in the
product mix sold.
Operating income for the quarter was $18.7 million (21.6% of revenues), representing a 10% increase compared to $17.0 million (20.0% of revenues) in Q1 2024. In local currencies, operating income grew by 17% year-over-year.
EBITDA for the quarter was $23.3 million (26.9% of revenues), up 4% from $22.3 million (26.3% of revenues) in the first quarter of last year. In local currencies, EBITDA grew by 12% year-over-year.
Net income for the quarter was $14.6 million (16.9% of revenues), or diluted earnings per share of $0.73, an increase of 12% compared to $13.0 million (15.3% of revenues), or $0.66 per diluted share, in the first quarter of 2024. In local currencies, net income grew by 20% year-over-year.
Cash flow from operations for the quarter was $15.5 million.
On the balance sheet, as of March 31, 2025, the Company had net cash, including marketable securities, of $75.7 million, which includes no debt. This is compared with net cash, including marketable securities, of $77.2 million, as of year-end 2024.
Dividend
The Board of Directors declared a dividend of $10 million
for the quarter. The current dividend takes into account the Company's
continuing strong profitability, ongoing positive cash flow, and strong
balance sheet.
About Ituran
Ituran is a leader in the emerging mobility technology field,
providing value-added location-based services, including a full suite of
services for the connected-car. Ituran offers Stolen Vehicle Recovery,
fleet management as well as mobile asset location, management &
control services for vehicles, cargo and personal security for the
retail, insurance, financing industries and car manufacturers. Ituran is
the largest OEM telematics provider in Latin America. Its products and applications are used by customers in over 20 countries. Ituran is also the founder of the Tel-Aviv based DRIVE startup incubator to promote the development of smart mobility technology.
Ituran's subscriber base has been growing significantly since the
Company's inception to over 2.5 million subscribers using its
location-based services with a market leading position in Israel and Latin America. Established in 1995, Ituran has approximately 2,800 employees worldwide, with offices in Israel, Brazil, Argentina, Mexico, Ecuador, Columbia, India, Canada and the United States.
Source: Ituran Location and Control Ltd. 5/27/2025
Ituran Location and Control Ltd. (NASDAQ: ITRN), a global leader in vehicle telematics, today announced a new service agreement with Stellantis in South America.
The contract covers multiple countries in the region and is set for a
multi-year period, with the potential for expansion to additional
markets and extended service periods.
Eyal Sheratzky, co-CEO of Ituran, commented, "We are excited
to enter this strategic partnership with Stellantis, bringing our
advanced stolen vehicle recovery and tracking solutions to their
customers across South America. Stellantis is the largest car manufacturer in Latin America,
which includes Fiat, Jeep, Peugeot and many others. Our goal is to
provide Stellantis drivers with a safer and more connected experience
while strengthening our position as a leading telematics provider in the
region. We anticipate this partnership will significantly expand our
subscriber base over the coming years."
Ituran is a leader in the mobility technology field, providing
value-added location-based services, including a full suite of services
for the connected-car. Ituran offers Stolen Vehicle Recovery, fleet
management as well as mobile asset location, management & control
services for vehicles, cargo and personal security for the retail,
insurance industry and car manufacturers. Ituran is the largest OEM
telematics provider in Latin America. Its products and applications are used by customers in over 20 countries. Ituran is also the founder of the Tel-Aviv based DRIVE startup incubator to promote the development of smart mobility technology.
Ituran's subscriber base has been growing significantly since the
Company's inception to approximately 2.5 million subscribers using its
location-based services with a market leading position in Israel and Latin America. Established in 1995, Ituran has approximately 3,000 employees worldwide, with offices in Israel, Brazil, Argentina, Mexico, Ecuador, Columbia, India, Canada and the United States.
Diabetinol® is a clinically supported and patented plant-based nutraceutical product targeting the pre-diabetic and weight loss marketplace
Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals"
or the "Company"), a company focused on developing, marketing, and
selling a variety of health and wellness products via a secure
telemedicine platform under the brands MangoRx and PeachesRx, today
announced that it has entered into a Master Distribution Agreement (the
“Agreement”) to secure the exclusive licensing and distribution rights
for Diabetinol® within the United States and Canada.
Diabetinol®
is a plant-based nutraceutical clinically supported and patented
extract of citrus peel rich in polymethoxylated flavones (PMFs),
including nobiletin and tangeretin. Based on clinical studies
performed, these compounds have demonstrated significant metabolic
effects, particularly in how the body processes and utilizes sugar and
fat. Mechanistically, Diabetinol® works by improving insulin
sensitivity, enhancing GLUT4-mediated glucose uptake in tissues,
suppressing hepatic glucose production, and activating key enzymes
involved in lipid metabolism. It also reduces systemic inflammation and
oxidative stress—two of the primary biological drivers of insulin
resistance and metabolic dysfunction.
Under the agreement, Mangoceuticals will hold the exclusive rights to market and sell Diabetinol® across the United States and Canada, expanding its product portfolio into the $33.66 billion addressable diabetes and metabolic health market.
“Millions
of people are left on the sidelines watching others lose weight using
drugs they can’t afford,” said Jacob Cohen, Founder and CEO of
Mangoceuticals, Inc., who continued, “Diabetinol® is not a
direct substitute for those prescription therapies, but the internal
studies have concluded that it does offer complementary metabolic
benefits in a safe, natural, and more affordable way. By harnessing
clinically proven plant-derived ingredients, we’re providing a new
option for individuals who cannot access or tolerate GLP-1 medications.
Our goal is to help more people take control of their blood sugar and
weight – safely, conveniently, and cost-effectively.”
Mangoceuticals’
expansion into metabolic health is timely given the escalating diabetes
crisis and the enormous total addressable market for such solutions. In
the U.S. alone, over 30 million Americans suffer from type 2 diabetes, and approximately 97.6 million American adults—more than one in three—have prediabetes. Globally, an estimated 537 million
adults are currently living with diabetes, and that number is expected
to rise to 783 million by 2045. If current trends continue, projections
suggest it could exceed 1.3 billion by 2050.
The healthcare burden associated with this is immense. U.S. diabetes-related healthcare costs are already over $400 billion per year. Meanwhile, global spending on weight loss and blood sugar–lowering medications reached $24 billion in 2023 and is projected to surpass $131 billion by 2028.
Currently, many people are prescribed metformin yet discontinue
second-line therapies due to cost or tolerability. With an estimated 50%
of Americans actively trying to lose weight at any given time, the demand for safer, more affordable metabolic health solutions is surging.
We believe that Diabetinol®
is well-positioned to fill that gap. As a naturally derived, clinically
supported nutraceutical, it offers a compelling option for consumers
who either can’t tolerate or access GLP-1 drugs, or who are seeking to
support their health with a non-pharmaceutical approach.
Mangoceuticals intends to distribute Diabetinol®
in multiple consumer-friendly formats including capsules, a
ready-to-drink beverage, quick-release pouches, cookies, and gummies.
Each product will be carefully dosed to deliver consistent clinical
levels of Diabetinol’s active ingredients. Distribution is expected to
include direct-to-consumer online initiatives via our own website and
through online retailers, brick and mortar retail outlets, and affiliate
marketing channels.
Najla Guthrie, Founder of
KGK Synergize and a recognized leader in nutraceutical clinical
research, expressed strong support for Diabetinol’s role in addressing
metabolic dysfunction, “I believe that Diabetinol® has the
potential to revolutionize how we think about supporting metabolic
health. Its unique blend of natural citrus-derived compounds has been
shown to deliver meaningful improvements in glycemic control, lipid
profiles, and blood pressure—offering a safe and clinically validated
adjunct to conventional care for those with prediabetes or diabetes,”
said Guthrie. She further noted that Diabetinol’s formulation, centered
around compounds like nobiletin and tangeretin, has been shown in
rigorous clinical trials to improve glucose tolerance and lipid levels
without adverse impacts on liver, kidney, or other organ functions and
believes that these findings support Diabetinol as a safe,
science-backed option to help manage blood sugar and reduce risk factors
associated with cardiovascular disease.
Mr.
Cohen further added, “Obtaining the exclusive rights to Diabetinol is a
major milestone for Mangoceuticals. We are proud to introduce an
innovative, science-backed nutraceutical that aligns with our mission of
improving lives through safe and accessible wellness solutions.
Diabetinol’s arrival could not be more timely, as the world faces a
metabolic health epidemic and we have seen that patients are seeking
alternatives that are both effective and affordable. We believe
Diabetinol® can become an invaluable option for individuals
looking to take charge of their metabolic health, and we’re excited to
lead that charge.”
In recent years, there has
been growing public awareness around the need for cleaner, more natural
approaches to health and wellness. Leaders in the national health
conversation, including newly appointed United States Secretary of
Health and Human Services, Robert F. Kennedy Jr., have emphasized the
importance of reducing reliance on synthetic pharmaceuticals in favor of
preventive, plant-based solutions, where appropriate. We believe that
Diabetinol® reflects this shift—offering a science-backed,
naturally derived option for those seeking to support their metabolic
health with fewer chemicals and greater transparency.
About Diabetinol® Clinical Studies
In a 3-month pilot study involving participants with impaired glucose metabolism, Diabetinol®
was shown to reduce peak postprandial blood glucose by approximately 50
mg/dL following a glucose challenge test. This reduction is considered
clinically meaningful, as it eases the burden on pancreatic beta cells
and lowers the risk of long-term damage caused by repeated glucose
spikes. Diabetinol® helped participants stabilize blood sugar
responses after meals, which is essential for preserving insulin
function and preventing complications associated with hyperglycemia.
In
a 6-month randomized, double-blind, placebo-controlled study of
patients with type 2 diabetes or prediabetes who were already on
conventional medications, Diabetinol® was shown to significantly improve a range of health markers. Among those taking Diabetinol®,
14.3% reached Hemoglobin A1c (HbA1c) targets (compared to 0% of the
placebo group), 33.3% reached LDL cholesterol goals (vs. 15.4% placebo),
20% reached total cholesterol goals (vs. 12.5% placebo), and 83.3%
reached systolic blood pressure goals (vs. 60% placebo). Participants
also experienced improved glucose tolerance over time, with a slower
rise in fasting glucose levels and improved Oral Glucose Tolerance Test
(OGTT) profiles—especially in individuals aged 40 to 60.
More information about Diabetinol® and the above clinical studies can be found online at www.Diabetinol.com.
About Mangoceuticals, Inc.
Mangoceuticals,
Inc. is focused on developing a variety of men’s and women’s health and
wellness products and services via a secure telemedicine platform. To
date, the Company has identified telemedicine services and products as a
growing sector and especially related to the area of erectile
dysfunction (ED), hair growth, hormone replacement therapies, and weight
management for men under the brands “MangoRx” and weight management
products for women under the brand “PeachesRx”. Interested consumers can
use MangoRx’s or PeachesRx’s telemedicine platform for a smooth
experience. Prescription requests will be reviewed by a physician and,
if approved, fulfilled and discreetly shipped through MangoRx’s and/or
PeachesRx’s partner compounding pharmacy and right to the patient’s
doorstep. To learn more about MangoRx’s mission and other products,
please visit www.MangoRx.com. To learn more about PeachesRx, please visit www.PeachesRx.com.
Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals"
or the "Company"), a company focused on developing, marketing, and
selling a variety of men’s wellness products via a secure telemedicine
platform under the brand MangoRx, proudly announces the official launch
of PeachesRx, an innovative women’s health and wellness brand focused on
providing cutting-edge, convenient treatments tailored to women’s
unique health needs. These new and innovative women’s health and
wellness products will be made available via a secure telemedicine
platform located at www.PeachesRx.com.
PeachesRx
will debut with a strong focus on compounded GLP-1 receptor agonists—a
class of medications proven to aid weight loss by regulating appetite
and glucose metabolism. Recent studies show that approximately 70%
of GLP-1 prescriptions for weight loss are written for women,
reflecting their dominant role in driving the surge in demand for these
medications. By introducing its tailored GLP-1 offerings, PeachesRx aims
to meet the unique metabolic needs of women while providing an
accessible and affordable telehealth-driven solution.
Market
demand for GLP-1 weight loss treatments among women is expanding
rapidly. Industry projections estimate that the global GLP-1 market for
weight management will exceed $48 billion by 2030, with women comprising the majority of users. Additionally, the global women’s health market was valued at $49.33 billion in 2024
and is projected to reach $68.53 billion by 2030, growing at a 5.1%
CAGR. Within the U.S. women's telehealth market, growth is fueled by
increased awareness, the demand for remote care, and the rise of
personalized medicine. PeachesRx is well-positioned to capture this
market by delivering GLP-1 solutions tailored to women's health needs,
with seamless access through its HIPAA-compliant telemedicine platform.
"The
launch of PeachesRx is the natural next step in Mangoceuticals’
expansion as we continue to redefine direct-to-consumer healthcare
solutions," said Jacob Cohen, CEO and Founder of Mangoceuticals, who
continued, "We’ve seen the success of our telehealth platform for men,
and we believe there is an even greater opportunity in women’s health.
As we have seen with MangoRx in the men’s health market, brand trust,
accessibility, and innovative product offerings have been key to driving
MangoRx’s success. PeachesRx will follow this blueprint, ensuring that
women can confidently access clinically proven treatments tailored to
their needs.”
Women represent a dominant force in telehealth adoption, with studies showing that over 60%
of telehealth users are female. More than ever, women are seeking
convenient, personalized healthcare solutions, and Peaches aims to
revolutionize access by providing affordable, effective, and medically
supervised treatments via its secure, HIPAA-compliant telemedicine
platform.
"Women’s healthcare has been
underserved for too long. With PeachesRx, we are transforming access by
providing seamless, confidential, and medically backed care," said
Amanda Hammer, COO of Mangoceuticals, who continued, "Our goal is to
bring the same level of innovation, affordability, and accessibility
that has driven our success in men’s wellness."
Positioned
to be a leader in women’s telehealth, PeachesRx combines an intuitive
user experience with a commitment to high-quality care, meeting the
evolving needs of today’s healthcare consumers. By initially launching
with GLP-1 solutions, PeachesRx intends to lay the groundwork for
potential future expansion into broader wellness categories, including,
but not limited to, sexual health, hair growth, and hormone therapy
solutions. The Company plans to grow PeachesRx into a leader in women’s
telehealth.
About MangoRx
MangoRx
is focused on developing a variety of men’s health and wellness
products and services via a secure telemedicine platform. To date, the
Company has identified men’s wellness telemedicine services and products
as a growing sector and especially related to the area of erectile
dysfunction (ED), hair growth, hormone replacement therapies, and weight
management. Interested consumers can use MangoRx’s telemedicine
platform for a smooth experience. Prescription requests will be reviewed
by a physician and, if approved, fulfilled and discreetly shipped
through MangoRx’s partner compounding pharmacy and right to the
patient’s doorstep. To learn more about MangoRx’s mission and other
products, please visit www.MangoRx.com.
About PeachesRx
PeachesRx
is focused on developing a variety of women’s health and wellness
products and services via a secure telemedicine platform. To date, the
PeachesRx has identified weight management as the initial product
category for its initial launch. Interested consumers can use
PeachesRx’s telemedicine platform for a smooth experience. Prescription
requests will be reviewed by a physician and, if approved, fulfilled and
discreetly shipped through PeachesRx’s partner compounding pharmacy and
right to the patient’s doorstep. To learn more about PeachesRx’s
mission and other products, please visit www.PeachesRx.com.
Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals”
or the “Company”), a company focused on developing, marketing, and
selling a variety of innovative health solutions today announced that it
is advancing its research into respiratory illness prevention
technologies by focusing on finding a practical, everyday solution to
combat avian influenza viruses (H5N1), specifically within the poultry
industry.
The Company has engaged Vipragen
Biosciences, an AAALAC-accredited preclinical Contract Research
Organization (CRO) based in Mysuru, India (“Vipragen”), to conduct
independent efficacy studies aimed at developing an antiviral solution
for respiratory illnesses in humans. These studies are based on the
Company’s acquisition of patented respiratory illness prevention
technology from IntraMont Technologies, Inc. (“IntraMont”). Phase I
animal studies have already demonstrated significant efficacy in
reducing lung viral load, and the compounds are now advancing into Phase
II animal studies.
Mangoceuticals is leveraging
this same technology to assess the feasibility of a drinking
water-based application for poultry. The study is planned to focus on
testing the efficacy of this solution when administered through drinking
water and evaluating any necessary modifications to optimize its
effectiveness in preventing avian flu infections among poultry
populations.
Unlike traditional approaches that
rely on synthetic vaccines or pharmaceutical treatments, Mangoceuticals'
antiviral technology leverages Generally Recognized as Safe (GRAS)
ingredients added to poultry drinking water. This method, we believe,
may offer a simple, compliant, and non-pharmaceutical way to strengthen
immune defenses in poultry. Following the Phase I animal studies, which
concluded in late December, and pending promising results from the
ongoing Phase II studies, though no assurances can be made, the Company
believes this solution has the potential to be an effective tool in
reducing the spread of H5N1 avian flu.
The ongoing avian flu outbreak has inflicted catastrophic losses on the poultry industry, leading to the culling of more than 148 million birds
in the United States alone since 2022. These aggressive containment
measures have crippled egg and poultry production, disrupted global
supply chains, and sent consumer prices soaring. As of December 2024,
the national average price of eggs hit $4.15 per dozen, with forecasts predicting an additional 20% increase in 2025.
In
addition to direct losses from outbreaks, farms are extending
significant amounts of resources on biosecurity measures and disease
prevention strategies to protect flocks. Despite these costly efforts,
avian flu remains a persistent threat, requiring a more effective and
cost-efficient approach. Mangoceuticals' water-based antiviral
technology aims to significantly reduce these expenses by hopefully
providing a proactive, scalable, and easily deployable solution to help
prevent infections before they spread.
"The rise
in global avian flu outbreaks is not just an agricultural issue, it’s a
potential global health crisis," said Jacob Cohen, Founder and CEO of
Mangoceuticals, who continued, "Our initial animal study research has
indicated and already demonstrated significant efficacy in reducing
viral loads in respiratory illnesses, and now we’re taking the next step
to evaluate how this same technology may be applied through poultry
drinking water as a preventive measure. We believe that if proven
effective in studies, this could be a simple, everyday solution that
fits seamlessly into existing poultry farming practices while reducing
the financial strain on farmers."
With the global poultry market projected to reach $375.41 billion by 2030,
we believe that Mangoceuticals' water-based antiviral solution could,
if proven successful in further studies, revolutionize disease
prevention in livestock and provide poultry farmers with a powerful new
tool against avian flu while helping to lower industry-wide costs.
As
outbreaks continue to rise, Mangoceuticals remains committed to
delivering effective, simple, and scalable solutions that protect
livestock, stabilize the food supply, and prevent future pandemics. The
Company anticipates sharing final study results upon completion of the
study, while ensuring proper intellectual property protections ahead of
commercialization.
About MangoRx
MangoRx
is focused on developing a variety of men’s health and wellness
products and services via a secure telemedicine platform. To date, the
Company has identified men’s wellness telemedicine services and products
as a growing sector and especially related to the area of erectile
dysfunction (ED), hair growth, hormone replacement therapies, and weight
management. Interested consumers can use MangoRx’s telemedicine
platform for a smooth experience. Prescription requests will be reviewed
by a physician and, if approved, fulfilled and discreetly shipped
through MangoRx’s partner compounding pharmacy and right to the
patient’s doorstep.
